Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Md Mahfuzur RahmanDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0003-1965-9836
Andrea PennatiDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-8435-1999
Tavus AtajanovaDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Trishna DebnathDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Raad H AllawiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0009-0005-5548-5433
Ross O MeyersDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-6499-8111
Tracy J BergDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0009-0006-1560-7827
Zafer GurelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-6739-2166
Nataliya V UbohaDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Michael F BassettiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-5012-8596
Lu MaoDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-8626-9822
Paul M SondelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-0981-8875
Randall J KimpleDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-8336-8000
Christian M CapitiniCarbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-2276-6731
Quaovi H SodjiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-9469-1388
Jacques GalipeauDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-9374-1996
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-5558-3547
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI WEICHERT, JAMEY P · 2020 to 2024
$12.5M
Novel Statistical Methods for Complex Time-to-Event Data in Cardiovascular Clinical TrialsR01HL149875 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Lu Mao · 2020 to 2026
$2.4M
Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against NeuroblastomaK08CA285941 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Quaovi H Sodji · 2024 to 2026
Pancreatic ductal adenocarcinoma (PDAC) is generally resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment (TME). We combine an innate cell-enriched product activated by interleukin-2 (IL-2) and zoledronic acid (ZA) (ICP
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models. · full record | OpenQuestion